Request for regulatory guidance for cancer cachexia intervention trials.
作者信息
Fearon Kch, Argiles J M, Baracos V E, Bernabei R, Coats Ajs, Crawford J, Deutz N E, Doehner W, Evans W J, Ferrucci L, Garcia J M, Gralla R J, Jatoi A, Kalantar-Zadeh K, Lainscak M, Morley J E, Muscaritoli M, Polkey M I, Rosano G, Rossi-Fanelli F, Schols A M, Strasser F, Vellas B, von Haehling S, Anker S D
机构信息
Clinical and Surgical Sciences, School of Clinical Sciences and Community Health, Royal Infirmary, University of Edinburgh Edinburgh, UK.
Biochemistry and Molecular Biology of Cancer, Faculty of Biology, University of Barcelona Barcelona, Spain.
出版信息
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):272-4. doi: 10.1002/jcsm.12083. Epub 2015 Nov 11.
Abstract
摘要
相似文献
1
Request for regulatory guidance for cancer cachexia intervention trials.癌症恶病质干预试验的监管指南申请。
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):272-4. doi: 10.1002/jcsm.12083. Epub 2015 Nov 11.
2
Clinical results in cachexia therapeutics.恶病质治疗的临床结果。
Curr Opin Clin Nutr Metab Care. 2016 May;19(3):199-204. doi: 10.1097/MCO.0000000000000274.
3
Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective.多模式管理作为抗恶病质药物临床应用的要求——监管与临床视角
Curr Opin Support Palliat Care. 2015 Dec;9(4):333-45. doi: 10.1097/SPC.0000000000000176.
4
Evidence base for multimodal therapy in cachexia.恶病质多模式治疗的循证医学。
Curr Opin Support Palliat Care. 2012 Dec;6(4):424-31. doi: 10.1097/SPC.0b013e328359b668.
5
Patient-reported outcomes in cancer cachexia clinical trials.癌症恶病质临床试验中的患者报告结局
Curr Opin Support Palliat Care. 2015 Dec;9(4):325-32. doi: 10.1097/SPC.0000000000000168.
6
Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.阿那莫林治疗癌症恶病质患者：两项 2 期、随机、安慰剂对照、双盲试验的综合分析。
Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16.
7
[Relationship of cytokine level with cancer cachexia and therapeutic effects of indomethacin for cancer cachexia].[细胞因子水平与癌性恶病质的关系及吲哚美辛对癌性恶病质的治疗作用]
Zhongguo Fei Ai Za Zhi. 2004 Aug 20;7(4):336-8. doi: 10.3779/j.issn.1009-3419.2004.04.16.
8
Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care.癌症恶病质与靶向慢性炎症：癌症治疗及姑息/支持治疗的统一方法
J Support Oncol. 2007 Apr;5(4):157-62; discussion 164-6, 183.
9
Cancer cachexia care: the contribution of qualitative research to evidence-based practice.癌症恶病质护理：定性研究对循证实践的贡献。
Cancer Nurs. 2012 Nov-Dec;35(6):E30-8. doi: 10.1097/NCC.0b013e31823d52b7.
10
Cancer cachexia: it's time for more clinical trials.癌症恶病质：是时候开展更多临床试验了。
Ann Surg Oncol. 2007 Feb;14(2):276-85. doi: 10.1245/s10434-006-9179-5. Epub 2006 Nov 9.
引用本文的文献
1
Multimodal interventions for cachexia management.用于恶病质管理的多模式干预措施。
Cochrane Database Syst Rev. 2025 Mar 25;3(3):CD015749. doi: 10.1002/14651858.CD015749.pub2.
2
Weight Gain Among Cancer Patients Receiving Chemotherapy-Facts and Numbers.接受化疗的癌症患者体重增加——事实与数据
J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13694. doi: 10.1002/jcsm.13694.
3
Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome.阿那莫林治疗癌症恶病质-厌食症综合征。
Curr Oncol Rep. 2024 Jul;26(7):762-772. doi: 10.1007/s11912-024-01549-y. Epub 2024 May 21.
4
Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series.癌症恶病质临床试验中的体重和组成终点：恶病质终点系列的系统评价 4。
J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):816-852. doi: 10.1002/jcsm.13478. Epub 2024 May 13.
5
Measuring What Is Meaningful in Cancer Cachexia Clinical Trials: A Path Forward With Digital Measures of Real-World Physical Behavior.衡量癌症恶病质临床试验中的有意义指标：通过数字手段测量真实世界身体行为的前进道路。
JCO Clin Cancer Inform. 2023 Sep;7:e2300055. doi: 10.1200/CCI.23.00055.
6
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series.癌症恶病质临床试验中的身体功能终点：恶病质终点系列的系统综述 1。
J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1932-1948. doi: 10.1002/jcsm.13321. Epub 2023 Sep 6.
7
Nutrition care is an integral part of patient-centred medical care: a European consensus.营养护理是以患者为中心的医疗护理的一个组成部分：欧洲共识。
Med Oncol. 2023 Mar 7;40(4):112. doi: 10.1007/s12032-023-01955-5.
8
Developing an Evidence and Theory Based Multimodal Integrative Intervention for the Management of Renal Cachexia: A Theory of Change.基于证据和理论开发用于管理肾性恶病质的多模式综合干预措施：一种变革理论
Healthcare (Basel). 2022 Nov 22;10(12):2344. doi: 10.3390/healthcare10122344.
9
Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial.选择性雄激素受体调节剂治疗慢性阻塞性肺疾病肌肉无力：一项随机对照试验。
Thorax. 2023 Mar;78(3):258-266. doi: 10.1136/thorax-2021-218360. Epub 2022 Oct 25.
10
Mapping ongoing nutrition intervention trials in muscle, sarcopenia, and cachexia: a scoping review of future research.绘制正在进行的肌肉、肌少症和恶液质营养干预试验图谱：未来研究的范围综述。
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1442-1459. doi: 10.1002/jcsm.12954. Epub 2022 Mar 17.
本文引用的文献
1
Treatment of cachexia: An overview of recent developments.恶病质的治疗：近期进展概述
Int J Cardiol. 2015 Apr 1;184:736-742. doi: 10.1016/j.ijcard.2014.10.026. Epub 2014 Oct 16.
2
Steps forward in regulatory pathways for acute and chronic heart failure.急性和慢性心力衰竭监管途径的进展。
Eur J Heart Fail. 2015 Jan;17(1):3-8. doi: 10.1002/ejhf.209.
3
Treatment of cachexia: an overview of recent developments.恶病质的治疗：近期进展概述。
J Am Med Dir Assoc. 2014 Dec;15(12):866-72. doi: 10.1016/j.jamda.2014.09.007. Epub 2014 Nov 20.
4
Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.肌肉减少症的流行率、发病率和临床影响：事实、数据和 2014 年的流行病学更新。
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):253-9. doi: 10.1007/s13539-014-0161-y. Epub 2014 Oct 22.
5
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014.恶病质的流行率、发生率和临床影响：事实和数据更新 2014 年版。
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3. doi: 10.1007/s13539-014-0164-8.
6
Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management.康复营养治疗伴失能的肌肉减少症：康复与营养照护管理相结合。
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):269-77. doi: 10.1007/s13539-014-0162-x. Epub 2014 Sep 16.
7
Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?抗阻运动：逆转血液透析患者肌肉消耗的有效策略？
J Cachexia Sarcopenia Muscle. 2014 Sep;5(3):177-80. doi: 10.1007/s13539-014-0160-z. Epub 2014 Aug 28.
8
Muscle strength and its relationship with skeletal muscle mass indices as determined by segmental bio-impedance analysis.肌肉力量及其与骨骼肌质量指数的关系，这些指数是通过节段生物阻抗分析确定的。
Eur J Appl Physiol. 2014 Jan;114(1):177-85. doi: 10.1007/s00421-013-2764-y. Epub 2013 Nov 1.
9
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation.美国胸科学会/欧洲呼吸学会官方声明：肺康复的关键概念和进展。
Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. doi: 10.1164/rccm.201309-1634ST.
10
Consensus-based standards for best supportive care in clinical trials in advanced cancer.癌症晚期临床试验中最佳支持治疗的基于共识的标准。
Lancet Oncol. 2012 Feb;13(2):e77-82. doi: 10.1016/S1470-2045(11)70215-7.
Zotero 插件